<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639546</url>
  </required_header>
  <id_info>
    <org_study_id>GO29665</org_study_id>
    <secondary_id>2014-004685-25</secondary_id>
    <nct_id>NCT02639546</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors</brief_title>
  <acronym>iMATRIXcobi</acronym>
  <official_title>A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients With Previously Treated Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, dose-escalation study is designed to evaluate the safety, tolerability,
      pharmacokinetics, and preliminary efficacy of cobimetinib in pediatric and young adult
      participants with solid tumors with known or potential kinase pathway activation for which
      standard therapy has proven to be ineffective or intolerable or for which no curative
      standard-of-care treatment options exist. The study will be conducted in two stages: a
      dose-escalation stage and an expansion stage at the recommended dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2016</start_date>
  <completion_date type="Anticipated">February 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD or MAD of Cobimetinib</measure>
    <time_frame>Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II Dose of Cobimetinib (RP2D)</measure>
    <time_frame>Cycle 1 Day 1 up to Cycle 1 Day 28 (cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration Observed (Cmax) of Cobimetinib</measure>
    <time_frame>Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (predose=within 4 hours prior to dose; cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Cobimetinib</measure>
    <time_frame>Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib</measure>
    <time_frame>Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of Cobimetinib</measure>
    <time_frame>Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Objective Response</measure>
    <time_frame>Baseline up to disease progression or death due to any cause, whichever occurs first (up to 6.75 years)</time_frame>
    <description>Tumor assessment will be performed using modified International Neuroblastoma Response Criteria (mINRC) for participants with neuroblastoma, Response Assessment in Neuro-Oncology (RANO) criteria for participants with high-grade glioma (HGG), and Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for participants with other tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by the Investigator</measure>
    <time_frame>Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 6.75 years)</time_frame>
    <description>Tumor assessment will be performed using mINRC for participants with neuroblastoma, RANO criteria for participants with HGG, and RECIST v1.1 for participants with other tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by the Investigator</measure>
    <time_frame>From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 6.75 years)</time_frame>
    <description>Tumor assessment will be performed using mINRC for participants with neuroblastoma, RANO criteria for participants with HGG, and RECIST v1.1 for participants with other tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline until death due to any cause (up to 6.75 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cobimetinib - Dose-Escalation Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.6 milligrams per kilogram (mg/kg) cobimetinib by mouth once daily on Days 1 to 21 of each 28-day treatment cycle. The dose will be increased by up to approximately 33% of the preceding dose level for each successive cohort until maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined. Once MTD or MAD has been identified in tablets, enrollment of participants using suspension will commence at a minimum of one dose level below MTD or MAD of the tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cobimetinib - Expansion Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the expansion stage, participants will be enrolled in disease-specific cohorts and treated at or below the MTD or MAD determined during the dose-escalation stage for pediatric participants and at the recommended adult dose for participants greater than or equal to (&gt;=) 18 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.</description>
    <arm_group_label>Cobimetinib - Dose-Escalation Stage</arm_group_label>
    <arm_group_label>Cobimetinib - Expansion Stage</arm_group_label>
    <other_name>RO5514041, GDC-0973, XL-518</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For dose-escalation stage (tablets): age at study entry &gt;= 6 years to &lt; 18 years

          -  For dose-escalation stage (suspension): age at study entry &gt;= 6 months to &lt; 18 years.
             Participants &lt;1 year of age will not be enrolled until &gt;= 6 participants &gt;= 1 year to
             &lt; 18 years of age have received at least one cycle of therapy with suspension and
             until safety and pharmacokinetic assessment of these participants have been conducted.

          -  For expansion stage: age at study entry to be &gt;= 6 months (&gt;=6 years if suspension is
             not available) to &lt; 30 years. Participants &gt;= 6 months to &lt; 1 year of age may not be
             enrolled until &gt;= 6 participants &gt;= 1 year to &lt; 18 years of age have received at least
             one cycle of therapy with suspension in the dose-escalation phase and until safety and
             pharmacokinetic assessment of these participants have been conducted.

          -  Tumor for which prior treatment has proven to be ineffective or intolerable or for
             which no standard therapy exists

          -  Tumor with known or expected RAS/RAF/MEK/ERK pathway involvement. Diagnosis must be
             one of the following tumor types:

        Central nervous system gliomas, including high- and low-grade gliomas, and diffuse
        intrinsic pontine glioma (DIPG) Embryonal rhabdomyosarcoma and other non-rhabdomyosarcoma
        soft tissue sarcomas Neuroblastoma Melanoma Malignant peripheral nerve sheath tumor
        Rhabdoid tumors, including atypical teratoid/rhabdoid tumor (ATRT) NF1-associated tumor
        (including plexiform neurofibroma), schwannoma, or RASopathy-associated tumor that in the
        judgment of the investigator is life threatening, results in severe symptoms (including
        severe pain), or is in close proximity to vital structures

          -  Measurable disease as defined by mINRC, RANO, RECIST v1.1, or evaluable by nuclear
             medicine techniques, immunocytochemistry, tumor markers, or other reliable measures

          -  Availability of tumor tissue at study enrollment

          -  Lansky performance status or Karnofsky performance status of &gt;= 50 percent

          -  Life expectancy &gt;= 3 months

          -  Adequate hematologic, cardiac, and end-organ function

          -  Body weight must be &gt;= 20 kilograms (kg) if suspension is not available

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Close proximity in time to treatment with high-dose chemotherapy, stem-cell rescue,
             differentiation therapy, immunotherapy, thoracic or mediastinal radiotherapy, hormonal
             therapy, biologic therapy, herbal cancer therapy, hematopoietic growth factor,
             investigational therapy, or St. John's wort according to protocol-defined criteria
             prior to initiation of study drug

          -  Inability to swallow oral medications

          -  Impaired gastrointestinal absorption

          -  History or evidence of retinal pathology according to protocol-defined criteria,
             including serous retinopathy

          -  History of Grade &gt;= 2 central nervous system (CNS) hemorrhage

          -  History of CNS hemorrhage within 28 days of study entry. This criterion may be waived
             at the investigator's request if the CNS hemorrhage was asymptomatic, with approval of
             the Medical Monitor

          -  Known active infection (excluding fungal infection of the nail beds) within 28 days
             prior to initiation of study drug that has not completely resolved

          -  Major surgical procedure or significant traumatic injury within 4 weeks prior to
             initiation of study drug, or anticipation of need for major surgical procedure during
             the course of the study

          -  Prior allogenic bone marrow transplantation or prior solid organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO29665 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Children'S Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University/Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hosp-Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alberta Children'S Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone, Oncologie Pédiatrique</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie, Oncologie Pédiatrique</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Des Enfants; Service d Hemato-Oncologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Service Pediatrique</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen; Department of Pediatric Oncology</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Zentrum f.Kinderheilkunde Klinik III</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH Standort Gieße; Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik Kinderheikunde I des Zentrums für Kinder- und Jugendmedizin, Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli; Oncologia Pediatrica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori; Struttura Complessa di Pediatria Oncologica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital For Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital; Paediatric Haematology &amp; Oncology</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hospital For Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary; Paediatric Oncology &amp; Haematology</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alderhey Childrens Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital; Dept. Of Pediatric Oncology</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Victoria Infirmary; Paediatric and Adolescent Oncology Unit</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Pediatric Unit</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

